Edotreotide
Also known as: 111In‑DTPA‑OC, 68Ga-DOTATOC, 90Y-DOTATOC, DOTA-D-Phe1-Tyr3-octreotide, DOTA-TOC, DTPA‑OC, Edotreotide DOTA, SomaKit TOC
Source Edotreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Radiolabeled peptide used for diagnostic scintigraphy of SSTR‑expressing tumors (e.g., neuroendocrine tumors). Administered intravenously and imaged with SPECT.
Mechanism of Action
Binds somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumor cells, delivering indium-111 for gamma‑camera imaging.
Routes of Administration
Goals & Uses
- Tumor detectionDiagnostic ImagingModerate
- Detection of paraganglioma and pheochromocytomaDiagnostic / ImagingModerate
- PET imaging of somatostatin receptor-positive neuroendocrine tumorsDiagnostic / ImagingHigh
- Peptide receptor radionuclide therapy (PRRT) of NETsOncology / TherapyModerate
- Tumor staging and restaging of neuroendocrine tumorsDiagnostic / ImagingHigh
Contraindications
- Hypersensitivity to somatostatin analogues or indium‑111 compoundsAllergyHigh
- Severe renal impairment (for 90Y-DOTATOC therapy)Organ ImpairmentHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
- Hypersensitivity to edotreotide or somatostatin analoguesAllergy / HypersensitivityHigh
Adverse Effects
- Radiation exposureRadiologicalUnknown
- Injection site reactionsLocalUncommon
- Radiation-induced secondary malignancyOncologicRare
- FlushingVascularCommonWarmth and redness of the skin
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- MyelosuppressionHematologicUncommon
- Transient hormonal effects (hypoglycemia, flushing)EndocrineUncommon
- NephrotoxicityRenalUncommon
Drug Interactions
- Chemotherapy agents causing myelosuppressionModerate
- Long-acting somatostatin analogues (octreotide LAR, lanreotide)Moderate
- Other radiopharmaceuticalsModerate
- Nephrotoxic agents (aminoglycosides, NSAIDs, cisplatin)High
Population Constraints
- Patients with bone marrow compromiseHematologicRelative
- Pediatric patientsAgeRelative
- Patients with renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionUnapprovedNo marketing authorization; limited clinical trial use.
- United StatesInvestigationalUsed under IND for diagnostic SPECT imaging.
- United KingdomApprovedApproved: PET imaging of somatostatin receptor-positive NETs (SomaKit TOC, post-Brexit recognition of EMA approval)Recognized following EMA approval; MHRA status aligns with EU for SomaKit TOC.
Not FDA‑approved; used under investigational new drug (IND) protocols for diagnostic imaging. No commercial brand in the US.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Edotreotide?
Radiolabeled peptide used for diagnostic scintigraphy of SSTR‑expressing tumors (e.g., neuroendocrine tumors). Administered intravenously and imaged with SPECT.
What is Edotreotide used for?
Edotreotide is educationally associated with: Tumor detection, Detection of paraganglioma and pheochromocytoma, PET imaging of somatostatin receptor-positive neuroendocrine tumors, Peptide receptor radionuclide therapy (PRRT) of NETs, Tumor staging and restaging of neuroendocrine tumors. Educational only — not medical advice.
How is Edotreotide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Edotreotide?
Reported adverse effects include: Radiation exposure, Injection site reactions, Radiation-induced secondary malignancy, Flushing, Nausea and vomiting, Nausea, Myelosuppression, Transient hormonal effects (hypoglycemia, flushing), Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Edotreotide?
Recorded contraindications: Hypersensitivity to somatostatin analogues or indium‑111 compounds, Severe renal impairment (for 90Y-DOTATOC therapy), Pregnancy, Breastfeeding, Hypersensitivity to edotreotide or somatostatin analogues. Consult a qualified clinician before use.